Lung cancer is the number one cancer killer in the world. Biomarker testing improves outcomes in stage IV non-small cell lung cancer (NSCLC), however its ...

Verastem, Inc.'s priority PDUFA date for avutometinib + defactinib in LGSOC set for June 2025; explore future data updates.

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients ...

Biomarker testing in advanced NSCLC has increased in recent years, but turnaround time has remained roughly the same, data suggest.

BeiGene has made the decision to end the clinical development program for ociperlimab (BGB-A1217) for the treatment of non-small cell lung cancer ...

Eighty-five percent of diagnosed cases of lung cancer are non-small cell lung cancer (NSCLC). In this group, 5% of patients show molecular alterations in the ALK gene involved in cell multiplication.

From new KRAS and HER2 inhibitors to home-administered immunotherapy, recent trials mark a turning point in how metastatic lung cancer is managed.

Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC), a common type of lung cancer, to study the development, activity, and ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

Curevac NV announced that the FDA has cleared its IND application for a phase I clinical study of CVHNLC in patients with ...

The firm will evaluate CVHNLC in combination with Keytruda as a first-line and first-line maintenance treatment in NSCLC.